

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of:

GARRILL et al.

Serial No.:

09/599,274

Group Art Unit: 3728

Filed:

June 22, 2000

Examiner: Jimmy G. Foster

For:

Method and Package for Storing a Pressurized Container Containing a Drug

Box Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[X] Copies of the references other than US patents are enclosed (References # 8-11 are on enclosed CD)							
		opies of the references were submitted in parent application Serial No (37 CFR 1.98(d))						
		copy of the International Search Report which issued on International Application No is						
		bmitted herewith. All of the publications cited in the International Search Report are listed on the						
		cached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent ffice by the International Bureau.						
Α.	[]	The Information Disclosure Statement submitted herewith is being filed within three months of the						
		filing date of the above application or date of entry into the national stage of an international						
		application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).						
	OR							
	[X]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a						
		first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114						
		(37 C.F.R. 1.97(b)(4)).						
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the						
	. ,	filing date of the above application or the date of entry into the national stage as set forth in § 1.491 o						
		an international application or after the mailing date of the first Office Action on the merits, whichever						
		event occurred last, but before the mailing date of either:						
		(1) a final action under § 1.113 or						
		(2) a notice of allowance under § 1.311,						
	whichever occurs first.							
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure						
		Statement was cited in a communication from a foreign patent office in a counterpart foreign						
		application not more than three months prior to the filing of this statement.						
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information						
		Disclosure Statement under \$ 1.97(c) (\$180.00)						

RECEIVED
DEC 2 9 2003

TECHNOLOGY CENTER 3700

C. []	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.									
In	In accordance with the requirements of 37 CFR 1.97(d):										
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.									
	[]	Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).									
	[]	The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.									
Please charge any required fees to Deposit Account No.07-1392.A duplicate copy of this paper is attached.											
Date)Cem	Respectfully Submitted, Atterney of Record: J. Michael Strickland									

Registration No.

47,115

GlaxoSmithKline Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-9024 Facsimile: (919) 483-7988

FORM PT); [#42.	DISCLOSURE ST	PATEMENT	ATTORNEY DOCKET NO.		SERIAL NO.			
1 /		<u>~</u>	ALEMENI		PG4114 APPLICANT		09/599,274		
1 6		<i>∑</i> /			GARRILL et al.				
NEC S	1 8 2003	, ଚା			FILING DATE GROUP				
Examiner Initials		(C106 30)			06/22/2000		3728		
173		 	USF	PATENT D	OCUMENTS		3720		
TADE	12/467 A 16-		0.5.1	OCCIMENTS		1	Filing Date		
Examiner	PAR	Patent	Issue Date	Name		Class	Subclass	If	
Initials		Number	133de Date	l	1 (unit		Subclass	Appropriate	
	1.	4,447,565	05/08/1984	Lula, et al	 		- 	† 	
	2.	4,757,919	07/19/1988	Smazik, e				 	
	3.	4,737,919	04/24/1990	Maruhash			<u> </u>		
				Hekal	i et al.		+	 	
	4.	5,062,569	11/05/1991					 	
	5.	5,591,379	01/07/1997	Shores			 		
	6.	5,789,044	08/04/1998	Ram et al		-			
	7.	6,328,327	12/11/2001	Ligony			<u> </u>		
	ļ		-	 					
		.,		ļ			<u></u>		
				<u> </u>					
			_	ļ <u></u>					
	<u> </u>			ļ. <u>-</u>					
				<u> </u>					
	<u>l</u> .								
								<u> </u>	
				<u> </u>					
				ontinue on j					
			FOREIG	N PATEN	T DOCUMENTS			_	
		Document	Publication					Translation	
		Number	Date		Country	Class	Subclass	Yes No	
	8.	96/04189	02/15/1996	PCT					
	9.	96/29603	09/26/1996	PCT					
	10.	96/33108	10/24/1996	PCT					
	11.	97/32663	09/12/1997	PCT					
	12.	4013799	04/28/1990	Germany	(abstract)				
	13.	2099940	01/07/1994	Canada (a	bstract)				
	14.	2306169	04/30/1997	Great Brit	tain (abstract)				
	15.	19633495	02/26/1998	Germany					
					· · · · · · · · · · · · · · · · · · ·				
					•				
			C	ontinue on	page				
		OTHER DOCUM			Title, Journal-Date	e, Page Numl	er, Etc.)		
								-	
			(Continue on	page				
EXAMINER	₹				DATE CONSIDERED				
					is in conformance w				
citation if no	t in con	formance and not	considered. Inclu	ide copy of	this form with next of				
							DECEN		

RECEIVEL

DEC 2 9 2003